scispace - formally typeset
D

Deborah Watson-Jones

Researcher at University of London

Publications -  135
Citations -  7347

Deborah Watson-Jones is an academic researcher from University of London. The author has contributed to research in topics: Population & Vaccination. The author has an hindex of 42, co-authored 116 publications receiving 6143 citations. Previous affiliations of Deborah Watson-Jones include Amref Health Africa & National Institute for Medical Research.

Papers
More filters
Journal ArticleDOI

Uptake of voluntary counselling and testing among young people participating in an HIV prevention trial: comparison of opt-out and opt-in strategies.

TL;DR: HIV voluntary counselling and testing uptake among young people was extremely high when offered an opt-out strategy, and increased with increasing knowledge of STI acquisition (males) or pregnancy prevention (females).
Journal ArticleDOI

Microbicides Development Program, Tanzania-Baseline Characteristics of an Occupational Cohort and Reattendance at 3 Months.

TL;DR: Baseline characteristics of this occupational group suggest their suitability for microbicide trials, and a screening round, locally appropriate informed consent procedures, and effective community tracing may help reduce losses to follow-up in such settings.
Journal ArticleDOI

Rapid acquisition of HPV around the time of sexual debut in adolescent girls in Tanzania

TL;DR: HP incidence was very high after first sex, including some vaccine genotypes, and infection duration was short, which supports recommendations that the HPV vaccine should be given to girls before first sex.
Journal ArticleDOI

Differences in health-related quality of life between HIV-positive and HIV-negative people in Zambia and South Africa: a cross-sectional baseline survey of the HPTN 071 (PopART) trial

TL;DR: ART is successful in helping to reduce inequalities in HRQoL between HIV-positive and HIV-negative individuals in this general population sample, and the importance of improving awareness of HIV status and expanding ART to prevent losses in HRZoL that occur with untreated HIV progression is highlighted.